Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;14(15):3636.
doi: 10.3390/cancers14153636.

Early Outcome, Cosmetic Result and Tolerability of an IOERT-Boost Prior to Adjuvant Whole-Breast Irradiation

Danny Jazmati  1 , Edwin Bölke  1 , Kati Halfmann  1 , Bálint Tamaskovics  1 , Eugen Ruckhäberle  2 , Tanja Fehm  2 , Jürgen Hoffmann  2 , David Krug  3 , Carolin Nestle Krämling  4 , Stefanie Corradini  5 , Wilfried Budach  1 , Svjetlana Mohrmann  2 , Jan Haussmann  1 , Christiane Matuschek  1
Affiliations

Early Outcome, Cosmetic Result and Tolerability of an IOERT-Boost Prior to Adjuvant Whole-Breast Irradiation

Danny Jazmati et al. Cancers (Basel). .

Abstract

Background/Aims: Due to its favorable dose distribution and targeting of the region at highest risk of recurrence due to direct visualization of tumor bed, intraoperative electron radiation therapy (IOERT) is used as part of a breast-conserving treatment approach. The aim of this study was to analyze tumor control and survival, as well as the toxicity profile, and cosmetic outcomes in patients irradiated with an IOERT boost for breast cancer. Materials and Methods: 139 Patients treated at our institution between January 2010 and January 2015 with a single boost dose of 10 Gy to the tumor bed during breast-conserving surgery followed by whole-breast irradiation were retrospectively analyzed. Results: 139 patients were included in this analysis. The median age was 54 years (range 28−83 years). The preferred surgical strategy was segmental resection with sentinel lymphonodectomy (66.5%) or axillary dissection (23.1%). Regarding adjuvant radiotherapy, the vast majority received 5 × 1.8 Gy to 50.4 Gy. At a median follow-up of 33.6 months, recurrence-free and overall survival were 95.5% and 94.9%, respectively. No patient developed an in-field recurrence. Seven patients (5.0%) died during the follow-up period, including two patients due to disease recurrence (non-in-field). High-grade (CTCAE > 2) perioperative adverse events attributable to IOERT included wound healing disorder (N = 1) and hematoma (N = 1). High-grade late adverse events (LENT-SOMA grade III) were reported only in one patient with fat necrosis. Low-grade late adverse events (LENT-SOMA grade I-II) included pain (18.0%), edema (10.5%), fibrosis (21%), telangiectasia (4.5%) and pigmentation change (23.0%). The mean breast retraction assessment score was 1.66 (0−6). Both patients and specialists rated the cosmetic result “excellent/good” in 84.8% and 87.9%, respectively. Conclusion: Our study reports favorable data on the cosmetic outcome as well as the acute and early long-term tolerability for patients treated with an IOERT boost. Our oncologic control rates are comparable to the previous literature. However, prospective investigations on the role of IOERT in comparison to other boost procedures would be desirable.

Keywords: LENT-SOMA; breast cancer; clinical outcome; radiation therapy; skin reaction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The Flow Diagram of our study.
Figure 2
Figure 2
Schematic representation of the IOERT-situs in the breast: blue: rib; brown: skin; yellow: breast parenchyma; white frame, red inside with green dots: tumor bed = clinical target volume (CTV); red: tubus. Before starting the radiation, the distance between surface of the tumor bed and the rib will be measured using intraoperative ultrasound (black arrow). The prescribed single dose is 10 Gy to the tumor bed (red isodose). The dose constraint for the rib is a maximum of 7 Gy (purple isodose). The skin is outside the tubus.
Figure 3
Figure 3
Plan and application of an IOERT.
Figure 4
Figure 4
Breast retraction assessment (BRA): BRA scoring is used to assess asymmetry of the breast. A score of 0 represents the best result (no asymmetry). This patient, for example, has a low score < 2 (minimal asymmetry).
See this image and copyright information in PMC

References

    1. Ghoncheh M., Pournamdar Z., Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac. J. Cancer Prev. 2016;17:43–46. doi: 10.7314/APJCP.2016.17.S3.43. - DOI - PubMed
    1. Salerno K.E. NCCN Guidelines Update: Evolving Radiation Therapy Recommendations for Breast Cancer. J. Natl. Compr. Cancer Netw. 2017;15:682–684. doi: 10.6004/jnccn.2017.0072. - DOI - PubMed
    1. Holland R., Veling S.H., Mravunac M., Hendriks J.H. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56:979–990. doi: 10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N. - DOI - PubMed
    1. Bartelink H., Horiot J.-C., Poortmans P.M., Struikmans H., Bogaert W.V.D., Fourquet A., Jager J.J., Hoogenraad W.J., Oei S.B., Wárlám-Rodenhuis C.C., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007;25:3259–3265. doi: 10.1200/JCO.2007.11.4991. - DOI - PubMed
    1. Romestaing P., Lehingue Y., Carrie C., Coquard R., Montbarbon X., Ardiet J.M., Mamelle N., Gérard J.P. Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1997;15:963–968. doi: 10.1200/JCO.1997.15.3.963. - DOI - PubMed

LinkOut - more resources